Progyny, Inc. (NASDAQ:PGNY) Given Average Rating of “Moderate Buy” by Brokerages

Progyny, Inc. (NASDAQ:PGNY) has been given an average rating of “Moderate Buy” by the twelve brokerages that are presently covering the company, Marketbeat.com reports. Four investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. The average 12 month price objective among brokerages that have covered the stock in the last year is $28.80.

A number of analysts have recently issued reports on the stock. Zacks Research lowered shares of Progyny from a “strong-buy” rating to a “hold” rating in a research note on Friday, January 30th. KeyCorp cut their price objective on shares of Progyny from $32.00 to $28.00 and set an “overweight” rating on the stock in a report on Monday. Weiss Ratings reissued a “hold (c)” rating on shares of Progyny in a research report on Monday, December 29th. Citigroup raised Progyny to an “outperform” rating in a research report on Tuesday, January 20th. Finally, Barclays started coverage on Progyny in a research note on Monday, December 8th. They issued an “overweight” rating and a $29.00 price target on the stock.

Progyny Price Performance

Shares of NASDAQ PGNY opened at $17.79 on Thursday. Progyny has a 1-year low of $16.75 and a 1-year high of $28.75. The business has a 50-day moving average of $23.40 and a 200-day moving average of $23.00. The company has a market capitalization of $1.46 billion, a price-to-earnings ratio of 27.37, a PEG ratio of 1.19 and a beta of 1.01.

Progyny (NASDAQ:PGNY) last announced its earnings results on Thursday, February 26th. The company reported $0.48 EPS for the quarter, beating the consensus estimate of $0.38 by $0.10. The business had revenue of $318.40 million for the quarter, compared to the consensus estimate of $314.26 million. Progyny had a return on equity of 11.37% and a net margin of 4.54%.The company’s revenue was up 6.7% on a year-over-year basis. During the same period last year, the business posted $0.42 EPS. Progyny has set its FY 2026 guidance at 1.830-1.950 EPS and its Q1 2026 guidance at 0.420-0.450 EPS. Research analysts expect that Progyny will post 0.6 EPS for the current fiscal year.

Insider Buying and Selling

In other Progyny news, EVP Allison Swartz sold 4,657 shares of the firm’s stock in a transaction on Tuesday, March 3rd. The shares were sold at an average price of $17.40, for a total transaction of $81,031.80. Following the completion of the transaction, the executive vice president directly owned 89,879 shares of the company’s stock, valued at $1,563,894.60. This trade represents a 4.93% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 9.40% of the stock is owned by company insiders.

Hedge Funds Weigh In On Progyny

Several large investors have recently modified their holdings of the stock. Royal Bank of Canada increased its holdings in Progyny by 384.8% in the first quarter. Royal Bank of Canada now owns 13,027 shares of the company’s stock valued at $291,000 after buying an additional 10,340 shares during the last quarter. Amundi grew its position in shares of Progyny by 103.8% in the 1st quarter. Amundi now owns 11,419 shares of the company’s stock worth $264,000 after acquiring an additional 5,817 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its holdings in shares of Progyny by 6.0% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 252,032 shares of the company’s stock valued at $5,630,000 after acquiring an additional 14,297 shares during the last quarter. Cetera Trust Company N.A raised its position in shares of Progyny by 303.1% during the 2nd quarter. Cetera Trust Company N.A now owns 1,310 shares of the company’s stock valued at $29,000 after acquiring an additional 985 shares in the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. raised its position in shares of Progyny by 357.9% during the 2nd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 116,138 shares of the company’s stock valued at $2,555,000 after acquiring an additional 90,775 shares in the last quarter. Institutional investors own 94.93% of the company’s stock.

About Progyny

Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.